NovoCure Limited Ordinary Shares Stock Prediction
AI-powered sentiment analysis and prediction trends for NVCR, updated each market day.
NVCR AI Sentiment
AI sees no strong directional signal for NovoCure Limited Ordinary Shares stock over the next 10 market days.
Prediction date: Sept. 23, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About NovoCure Limited Ordinary Shares
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
Sector
Exchange
Market Cap
$1,946,974,444
Cap Tier
Employees
1,605
Headquarters
ST. HELIER
Listed Since
Oct. 2, 2015
Website
NVCR Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
NVCR Volatility
NovoCure Limited Ordinary Shares has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
